Nerelimomab
Alternative Names: BAY 1351; BAY X 1351; NoraseptLatest Information Update: 02 Jul 1997
At a glance
- Originator Chiron Corporation
- Developer Celltech Group; Chiron Corporation
- Class Anti-TNF monoclonal antibodies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Septic shock
Most Recent Events
- 02 Jul 1997 Discontinued-I for Septic shock in Japan (IV)
- 02 Jul 1997 Discontinued-III for Septic shock in France (IV)
- 02 Jul 1997 Discontinued-III for Septic shock in Germany (IV)